Efficacy of leflunomide in the treatment of palindromic rheumatism. (6th June 2022)

• Record Type: Journal Article
• Authors: Sadri, Maryam; Esalatmanesh, Kamal; Khabbazi, Alireza
• Is Part Of: International journal of rheumatic diseases. Volume 25:Number 8(2022)
• Page Start: 893
• Page End: 896
• Publication Date: 2022-06-06
• Subjects: control of attacks -- conventional synthetic disease‐modifying antirheumatic drugs -- leflunomide -- palindromic rheumatism -- remission; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.14364
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Objective: The goal of treatment in palindromic rheumatism (PR) is to control the attacks and prevent disease evolution to chronic arthritis. Conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) including antimalarial and methotrexate cannot control attacks in all patients. Methods: In this retrospective study, we assessed the efficacy of leflunomide in patients with PR who had an inadequate response to DMARDs. In this study, patients who had a diagnosis of PR and were treated with leflunomide because of active disease despite treatment with csDMARDs for at least 6 months were included. Remission was defined as no attacks for 3 months and prednisolone dose ≤5 mg/d. Leflunomide treatment failure was defined as failure to achieve remission, the need to add other DMARDs for controlling attacks and disease progression to chronic arthritis during treatment with leflunomide. Results: Ten cases with active disease despite treatment with hydroxychloroquine and methotrexate and low‐dose prednisolone treated with leflunomide were included in the study. During the 12.6 ± 7.5 months of treatment with leflunomide, the frequency of attacks significantly decreased. Complete and partial remission were achieved in 90% of patients. Conclusion: Our results indicate that leflunomide controls PR attacks and it might be a new option for patients with PR.